Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
This article compares Eli Lilly and Viking Therapeutics in the booming GLP-1 drug market, highlighting each company's strengths and weaknesses from a neutral investment perspective.
The GLP-1 (glucagon-like peptide-1 receptor agonists) drug market is experiencing massive growth, making it an attractive arena for investment in companies like Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX). This analysis aims to provide a neutral comparison between the two stocks to help investors understand the opportunities and risks.
Rating Change
There is no specific analyst rating change in this article; it is a general comparative analysis. Eli Lilly is an established company with approved products, while Viking Therapeutics is a smaller company in the development stage.
Analyst Rationale
The analysis focuses on the growth potential of the GLP-1 market. Eli Lilly has approved drugs such as Mounjaro and Zepbound, giving it current revenue and market share. In contrast, Viking Therapeutics has a promising candidate (VK2735) in late-stage clinical trials, offering higher growth potential but with greater risk.
Context
Eli Lilly's stock performance is relatively stable due to its approved products, while Viking Therapeutics' stock is highly sensitive to clinical trial results and regulatory developments. Other analysts view Eli Lilly as a safe bet in the sector, while Viking represents a high-risk/high-reward play.
What to Conclude
The choice between the two stocks depends on the investor's goals and risk tolerance. Eli Lilly is suitable for investors seeking a stable investment in an established company, while Viking may appeal to those looking for exponential growth with higher risk.
Frequently Asked Questions
Found this useful? Share it